SCHEMBL84139

SCHEMBL84139

NC(=S)c1cc(F)ccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.56
CES1 P23141 3/20 0.56
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
KEAP1 Q14145 1/20 0.41
ALDH1A1 P00352 2/20 0.39
PPP5C P53041 1/20 0.39
CTSL P07711 2/20 0.37
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN2C Q14957 2/20 0.36
GRIN3A Q8TCU5 2/20 0.36
KDM1A O60341 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2034076 0.82 CES2 (0.56) CES2CES1CA3CA6CA5A
SCHEMBL15609067 0.78 DGAT1 (0.50) CES2ALDH1A1PPP5CCTSLKDM1A
SCHEMBL6889081 0.78 KEAP1 (0.38) CES2CES1KEAP1ALDH1A1PPP5C
SCHEMBL29537903 0.77 CES2 (0.68) CES2CES1CA3CA6CA5A
SCHEMBL4426660 0.77 CES2 (0.56) CES2CES1CA3CA6CA5A
SCHEMBL12289224 0.77 CES2 (0.56) CES2CES1CA3CA6CA5A
SCHEMBL366058 0.77 CES2 (0.68) CES2CES1CA3CA6CA5A
SCHEMBL20560609 0.77 CES2 (0.56) CES2CES1CA3CA6CA5A
SCHEMBL801104 0.77 CES2 (0.50) CES2CES1CA3CA6CA5A
SCHEMBL27673772 0.76 CES2 (0.74) CES2CES1CA3CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091926-B1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2015-10-21 EP disclosed
US-8748626-B2 Oxazole and thiazole compounds as KSP inhibitors NOVARTIS AG (CH) 2014-06-10 US disclosed
US-8748626-B2 Oxazole and thiazole compounds as KSP inhibitors NOVARTIS AG (CH) 2014-06-10 US disclosed
US-8748626-B2 Oxazole and thiazole compounds as KSP inhibitors NOVARTIS AG (CH) 2014-06-10 US disclosed
US-20140056880-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2014-02-27 US disclosed
US-20140056880-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2014-02-27 US disclosed
US-20140056880-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2014-02-27 US disclosed
US-8546434-B2 Triazole compounds as KSP inhibitors NOVARTIS AG (CH) 2013-10-01 US disclosed
US-8546434-B2 Triazole compounds as KSP inhibitors NOVARTIS AG (CH) 2013-10-01 US disclosed
US-8546434-B2 Triazole compounds as KSP inhibitors NOVARTIS AG (CH) 2013-10-01 US disclosed
US-7902240-B2 Kinesin spindle protein (KSP); anticancer agents; antiproliferative agents; e.g. N-((S)-3-amino-4-fluorobutyl)-N ((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide NOVARTIS AG (CH) 2011-03-08 US disclosed
US-20100034813-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2010-02-11 US disclosed
US-20100034813-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2010-02-11 US disclosed
US-20080200462-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG 2008-08-21 US disclosed
US-20080200462-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG 2008-08-21 US disclosed
WO-2008063912-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS NOVARTIS AG (CH) 2008-05-29 WO disclosed
US-7335674-B2 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) (FR) 2008-02-26 US disclosed
US-20060135573-A1 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof IPSEN PHARMA S.A.S. (FR) 2006-06-22 US disclosed
EP-1641789-A2 BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-04-05 EP disclosed
WO-2005000843-A2 BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135573-A1 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof CDC25A, CDC25C, CDC25B CES2 2475/4885CES1 1748/4885CA3 1779/4885
US-20100034813-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS CYP3A43, ABCG2, CYP3A7 CES2 936/4885CES1 113/4885CA3 3028/4885
US-20080200462-A1 SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS CYP3A43, ABCG2, CYP3A7 CES2 936/4885CES1 113/4885CA3 3028/4885
US-20140056880-A1 TRIAZOLE COMPOUNDS AS KSP INHIBITORS CYP17A1, CYP51A1, KLKB1 CES2 1111/4885CES1 86/4885CA3 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.